Rheumatology Advisor Contributing Writer

Researchers conducted a systematic review to study factors and outcomes associated with sarcopenia in rheumatoid arthritis.

Researchers studied the causes and outcomes of biologics switching among patients with juvenile idiopathic arthritis.

A subanalysis of the AVERT-2 study was aimed at determining whether patients whose RA was in remission were able to sustain remission to 1 year following changes in therapy.

This is a comprehensive table of rheumatology ICD 10 codes used by researchers as well as healthcare professionals and personnel.

Researchers studied the effect of gout on cardiovascular events, including CVD and heart failure, in a Black urban population.

Researchers studied the clinical characteristics of patients with rheumatoid arthritis associated interstitial lung disease.

Researchers studied the safety and efficacy of golimumab treatment withdrawal among patients with active nonradiographic axial spondyloarthritis.

Researchers sought to evaluate the incidence of major adverse cardiovascular events in French patients with ankylosing spondylitis.

A study was conducted to assess changes in bone mineral density following discontinuation of denosumab in patients recovering from subacute spinal cord injury.

The benefits and effectiveness of the fourth dose of the COVID-19 vaccine were assessed among patients with autoimmune rheumatic disease.

The aim of the post hoc analysis was to analyze the efficacy of upadacitinib among patients with moderately active rheumatoid arthritis.

Using data from 2 parallel trials (BE MOBILE 1 and 2), researchers studied the safety and efficacy of bimekizumab among patients with axial spondyloarthritis.

Researchers studied the development of atrial fibrillation after treatment with different urate-lowering therapies in Asian patients with gout.

Researchers studied the safety and efficacy of tigulixostat in lowering serum urate levels among patients with gout and hyperuricemia.

In a post hoc analysis, researchers compared the efficacy of subcutaneous vs intravenous infliximab among patients with RA.

Researchers studied the factors associated with changes in health-related quality of life among patients with gout in primary care.

Using data from 7 clinical trials, researchers studied the effect of continuation of glucocorticoids after initial bridging therapy among patients with RA.

Researchers determined the effect of fatigue on assessment of disease activity in patients with systemic lupus erythematosus.

Using NHANES data, researchers estimated the prevalence of chronic axial pain, inflammatory back pain, axial spondyloarthritis, and peripheral arthritis in inflammatory bowel disease.

Predictors of serious infection among patients with SLE were evaluated in a prospective study.

Researchers compared severe COVID-19 outcomes among patients with rheumatoid arthritis across phenotypic subgroups.

Researchers determined the effect of sustained glucocorticoid tapering among patients with SLE.

Researchers determined the effect of depression and anxiety on disease activity among patients with psoriatic arthritis.

Researchers examined the associations between environmental and societal factors and variations in COVID-19-related mortality in those with rheumatic diseases.

Researchers evaluated the analgesic effects of naltrexone plus transcranial direct current stimulation in patients with fibromyalgia.

Researchers applied the Lupus Low Disease Activity State definition within a large cohort of patients to assess the relationship between it and physician evaluations.

Researchers assessed the differences in clinical characteristics, disability, quality of life, and work productivity by sex in psoriatic arthritis.

Researchers examined outcomes and adverse events associated with rituximab therapy in older adult patients with ANCA-associated vasculitis.

Researchers explored whether inactivated COVID-19 vaccine influences prothrombotic autoantibodies in antiphospholipid syndrome.

Researchers analyzed bone mineral density changes following denosumab therapy for osteoporosis.